Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654193 | 1.00 | GAA (0.42) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6656232 | 0.96 | FAAH (0.41) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6660462 | 0.94 | GAA (0.43) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6651888 | 0.93 | ALOX15 (0.43) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6654149 | 0.93 | ALOX15 (0.43) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6654153 | 0.92 | GAA (0.42) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6652567 | 0.90 | ALOX15 (0.44) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6652212 | 0.90 | ALOX15 (0.44) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6651494 | 0.89 | ALOX15 (0.42) | GAAFAAHALOX15PDE4BKDM1A | |
| SCHEMBL6656848 | 0.89 | ALOX15 (0.42) | GAAFAAHALOX15PDE4BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167163-A1 | Optically pure paroxetine precursors | ASTUR-PHARMA, S.A. (ES) | 2004-08-26 | — | — | US | disclosed |
| EP-1431287-A1 | Optically pure paroxetine precursos | Astur-Pharma, S.A. (ES) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167163-A1 | Optically pure paroxetine precursors | CYP3A5, TPH2, MAOA | GAA 299/4885FAAH 31/4885ALOX15 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.